A Study of SC-007 in Subjects With Advanced Cancer

Inclusion Criteria:

- Histologically or cytologically confirmed advanced metastatic or unresectable advanced
colorectal cancer (CRC) or gastric cancer that is relapsed, refractory, or progressive
after:

- CRC: at least 2 prior systemic regimens in the metastatic setting, and as appropriate
in patients whose tumors are microsatellite instability-high (MSI-H), pembrolizumab as
well.

- Gastric cancer (including gastric and EGJ cancers): at least 2 prior systemic regimens
in adjuvant, advanced, or metastatic setting and, as appropriate, a human epidermal
growth factor receptor 2 (HER2) targeted agent.

- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

- Adequate hematologic, hepatic, and renal function.

Exclusion Criteria:

- Any significant medical condition that, in the opinion of the investigator or sponsor,
may place the participant at undue risk from the study.

- Has electrocardiogram (ECG) abnormalities that make QT interval corrected (QTc)
evaluation difficult.

- Prior exposure to a pyrrolobenzodiazepine or indolinobenzodiazepine based drug.